Medical
NEW
KEYNOTE-483 and the September 2024 FDA Approval Reshaping First-Line Mesothelioma Treatment (2026)
David Foster
May 18, 2026
KEYNOTE-483 added pembrolizumab to chemo, extending pleural mesothelioma median survival to 17.3 months. What the Sept 2024 FDA approval means in 2026.
12 min read 7 FAQs
Read